Lyell Immunopharma Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After the Company Announced Yesterday It Will Present Clinical Data From Its Phase 1-2 Trial of IMPT-314 CAR T-cell Therapy for B-cell Lymphoma at ASH 2024.
Lyell Immunopharma Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After the Company Announced Yesterday It Will Present Clinical Data From Its Phase 1-2 Trial of IMPT-314 CAR T-cell Therapy for B-cell Lymphoma at ASH 2024.
Lyell免疫藥股票交易上漲。該股可能由於公司昨天宣佈將在2024年ASH大會上發佈IMPt-314 CAR t-細胞療法用於b細胞淋巴瘤的臨床數據而繼續走強。
Lyell Immunopharma Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After the Company Announced Yesterday It Will Present Clinical Data From Its Phase 1-2 Trial of IMPT-314 CAR T-cell Therapy for B-cell Lymphoma at ASH 2024.
Lyell免疫藥股票交易上漲。該股可能由於公司昨天宣佈將在2024年ASH大會上發佈IMPt-314 CAR t-細胞療法用於b細胞淋巴瘤的臨床數據而繼續走強。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間